Abstract: A process for isolating or extracting rare cells from a biological sample comprising filtering a biological sample, which may be treated or diluted, through a filter that has a pore size, pore density or other physical properties that retain rare cells, but which permits other kinds of cells to pass through the filter. This process also comprises multiple analyses performed on rare cells after their extraction or isolation by filtration to diagnostically identify the presence of rare cells in a biological sample and to use their diagnostic identification and molecular characterization for diagnostic purposes such as for early diagnosis of diseases, namely for early diagnosis of cancer and to select, guide, monitor treatments and in particular to select targeted treatments and to monitor the response and/or resistance to them.

Abstract: An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.

Abstract: The present invention relates to a method for diagnosing and/or prognosing a pathology (such as inflammatory disease, especially Crohn disease) associated with a synonymous mutation occurring within a gene of interest (such as IRGM, NOD2 or BSN) in a subject and to a method for treating such pathology in a subject.

Abstract: A process for isolating or extracting rare cells from a biological sample comprising filtering a biological sample, which may be treated or diluted, through a filter that has a pore size, pore density or other physical properties that retain rare cells, but which permits other kinds of cells to pass through the filter. This process also comprises multiple analyses performed on rare cells after their extraction or isolation by filtration to diagnostically identify the presence of rare cells in a biological sample and to use their diagnostic identification and molecular characterization for diagnostic purposes such as for early diagnosis of diseases, namely for early diagnosis of cancer and to select, guide, monitor treatments and in particular to select targeted treatments and to monitor the response and/or resistance to them.

Abstract: An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.

Abstract: The present invention relates to a method for diagnosing and/or prognosing a pathology (such as inflammatory dis-ease, especially Crohn disease) associated with a synonymous mutation occurring within a gene of interest (such as IRGM, NOD2 or BSN) in a subject and to a method for treating such pathology in a subject.

Abstract: Method for rendering smooth teletext graphics, when an input teletext page (D1) is to be displayed at a target resolution on a device. The method comprises the steps of:—separating (100) non-text information and text information composing the input teletext page (D1) in order to give as output an intermediate non-text bitmap (D5) at an intermediate resolution and a final text bitmap (D4) at said target resolution;—scaling up (200) the intermediate non-text bitmap (D5) to obtain a final non-text bitmap (D7) at said target resolution, using an advanced up-scaling algorithm; and,—merging (300) the final non-text bitmap (D7) and the final text bitmap (D4) in order to give an output of a rendered bitmap (D) having the target resolution.

Abstract: The application relates to the treatment of conditions and diseases for which growth hormone is a desirable method of treatment, using free fatty acid regulators in combination with growth hormone. In particular, the present invention discloses an enhanced method of treatment of growth disorders as well as methods to prevent and/or reduce adverse consequences of growth hormone treatment.

Abstract: A block artifacts detection device (100) for detecting block artifacts in a video signal is disclosed. The block artifacts detection device (100) comprises: computing means (102) for computing a gradient signal on basis of the video signal; establishing means (104) for establishing a list of samples corresponding to respective local maximum values of the gradient signal; a histogram determining means (106) for determining a histogram of inter-sample distances, a first one of the inter-sample distances corresponding to a first distance between a first one of the samples and a second one of the samples succeeding the first one of the samples, and a second one of the inter-sample distances corresponding to a second distance between the first one of the samples and a third one of the samples succeeding the second one of the samples; and analyzing means (108) for analyzing the histogram of inter-sample distances and for producing a block artifact indicator on basis of the histogram.

Abstract: This invention provides compositions and methods for treating adverse effects of growth hormone therapy in animals that are small for gestational age or suffered from intrauterine growth restriction. Methods include providing growth hormone to increase growth rates, and includes co-administration of an insulin sensitiser, such as a biguanide or a thiazolidinedione. In other embodiments, combinations of insulin sensitisers can be co-administered along with growth hormone.